Evidence map›Paper›PMID 39381015›Full record

ArticleTransplant international : official journal of the European Society for Organ Transplantation2024

High-Risk HLA-DQ Mismatches Are Associated With Adverse Outcomes After Lung Transplantation.

Lisa Kleid, Julia Walter, Patrick Moehnle, Christian Wichmann, Julia Kovács, Andreas Humpe, Christian Schneider, Sebastian Michel, Nikolaus Kneidinger, Michael Irlbeck and 3 more

Abstract read
In one paragraph

Article in Transplant international : official journal of the European Society for Organ Transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lisa Kleid *Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany.
Julia Walter *Division of Thoracic Surgery, University Hospital, LMU Munich, Munich, Germany.
Patrick MoehnleDivision of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany.
Christian WichmannDivision of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany.
Julia KovácsDivision of Thoracic Surgery, University Hospital, LMU Munich, Munich, Germany.
Andreas HumpeDivision of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany.
Christian SchneiderDivision of Thoracic Surgery, University Hospital, LMU Munich, Munich, Germany.
Sebastian MichelComprehensive Pneumology Center (CPC), Helmholtz Munich, Member of the German Center of Lung Research (DZL), LMU Munich, Munich, Germany.
Nikolaus KneidingerComprehensive Pneumology Center (CPC), Helmholtz Munich, Member of the German Center of Lung Research (DZL), LMU Munich, Munich, Germany.
Michael IrlbeckDepartment of Anaesthesiology, University Hospital, LMU Munich, Munich, Germany.
Jan FertmannDivision of Thoracic Surgery, University Hospital, LMU Munich, Munich, Germany.
Andrea Dick *Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany.
Teresa Kauke *Division of Thoracic Surgery, University Hospital, LMU Munich, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human leukocyte antigen (HLA) mismatches (MM) between donor and recipient lead to eplet MM (epMM) in lung transplantation (LTX), which can induce the development of de-novo donor-specific HLA-antibodies (dnDSA), particularly HLA-DQ-dnDSA. Aim of our study was to identify risk factors for HLA-DQ-dnDSA development. We included all patients undergoing LTX between 2012 and 2020. All recipients/donors were typed for HLA 11-loci. Development of dnDSA was monitored 1-year post-LTX. EpMM were calculated using HLAMatchmaker. Differences in proportions and means were compared using Chi2-test and Students' t-test. We used Kaplan-Meier curves with LogRank test and multivariate Cox regression to compare acute cellular rejection (ACR), chronic lung allograft dysfunction (CLAD) and survival. Out of 183 patients, 22.9% patients developed HLA-DQ-dnDSA. HLA-DQ-homozygous patients were more likely to develop HLA-DQ-dnDSA than HLA-DQ-heterozygous patients (

Indexed as

Graft RejectionHLA-DQ AntigensLung TransplantationAdultFemaleGraft SurvivalHistocompatibility TestingHumansIsoantibodiesMaleMiddle AgedRetrospective StudiesRisk FactorsTissue DonorsHLA-DQ AntigensIsoantibodiesde novo donor specific antibodyeplet matchingHLA-DQ antibodylung transplantationrisk-stratification

Identifiers

PMID39381015
PMCPMC11460317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.